Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy
Authors
Keywords
Interleukin 6, Gastric cancer, Survival, Prognosis, Chemotherapy, Polymorphism
Journal
BMC CANCER
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-05-22
DOI
10.1186/1471-2407-14-357
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications
- (2013) G. G. Van den Eynden et al. CANCER RESEARCH
- A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
- (2013) R. Kurzrock et al. CLINICAL CANCER RESEARCH
- IL-6 polymorphisms: a useful genetic tool for inflammation research?
- (2013) Patricia Woo et al. JOURNAL OF CLINICAL INVESTIGATION
- Favorable Responses to Tocilizumab in Two Patients With Cancer-Related Cachexia
- (2013) Haruhiko Hirata et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Cytokine patterns in patients with cancer: a systematic review
- (2013) Bodo E Lippitz LANCET ONCOLOGY
- Interleukin-6 Mediates Epithelial–Stromal Interactions and Promotes Gastric Tumorigenesis
- (2013) Hiroto Kinoshita et al. PLoS One
- Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases
- (2013) Ricardo C. Ferreira et al. PLoS Genetics
- Interleukin-6 signaling pathway in targeted therapy for cancer
- (2012) Yuqi Guo et al. CANCER TREATMENT REVIEWS
- Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
- (2012) Kenneth C.H. Fearon et al. Cell Metabolism
- Hitting a complex target: an update on interleukin-6 trans-signalling
- (2012) Georg H Waetzig et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
- (2012) Stefan Rose-John International Journal of Biological Sciences
- Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases
- (2012) Toshio Tanaka et al. International Journal of Biological Sciences
- A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
- (2012) Gary Hudes et al. INVESTIGATIONAL NEW DRUGS
- Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
- (2012) Pasquale Sansone et al. JOURNAL OF CLINICAL ONCOLOGY
- Possible Role for Tocilizumab, an Anti–Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia
- (2012) Katsutoshi Ando et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
- (2012) Hai T Tran et al. LANCET ONCOLOGY
- Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population
- (2012) Hasan Korkaya et al. MOLECULAR CELL
- An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification
- (2011) O. W. Stephens et al. BLOOD
- Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells
- (2011) W Okamoto et al. BRITISH JOURNAL OF CANCER
- Metastatic Cells Can Escape the Proapoptotic Effects of TNF- through Increased Autocrine IL-6/STAT3 Signaling
- (2011) S. Li et al. CANCER RESEARCH
- A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
- (2011) Trevor J Bayliss et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer
- (2010) Chi-Wen Lo et al. CANCER RESEARCH
- Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer
- (2009) Do-Kyong Kim et al. BMC CANCER
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer
- (2009) A. DeMichele et al. CANCER RESEARCH
- Prognostic Significance of Interleukin-6 Single Nucleotide Polymorphism Genotypes in Neuroblastoma: rs1800795 (Promoter) and rs8192284 (Receptor)
- (2009) J. P. Lagmay et al. CLINICAL CANCER RESEARCH
- Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells
- (2009) N J Sullivan et al. ONCOGENE
- IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines
- (2008) Raquel Mejías-Luque et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
- (2008) V Catalano et al. BRITISH JOURNAL OF CANCER
- Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma
- (2008) W.-C. Liao et al. CLINICAL CANCER RESEARCH
- Cytokine and cytokine receptor gene polymorphisms and their functionality
- (2008) Andrew J.P. Smith et al. CYTOKINE & GROWTH FACTOR REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started